“7 Most Promising Drugs in the Parkinson’s Disease Treatment Pipeline”

While levodopa remains the gold standard for symptom management, several innovative treatments are in development: 1. ND0612 (Mitsubishi Tanabe Pharma/NeuroDerm): A 24-hour subcutaneous infusion system delivering levodopa/carbidopa to address motor fluctuations. 2. Tavapadon (Cerevel Therapeutics/AbbVie): A daily oral therapy targeting dopamine D1/D5 receptors, improving motor function with fewer side effects. 3. P2B001 (Pharma Two B): A combination of pramipexole and rasagiline designed for effective symptom management with reduced side effects. 4. BIIB122/DNL151 (Biogen/Denali Therapeutics): An LRRK2 inhibitor aiming to slow disease progression by restoring lysosomal function. 5. Buntanetap (Annovis Bio): Targets toxic proteins linked to neurodegeneration, potentially slowing progression and improving motor function. 6. Solengepras (Cerevance): A non-dopaminergic therapy modulating the indirect motor pathway to reduce “OFF” time and improve symptoms. 7. Minzasolmin (UCB Biopharma/Novartis): An alpha-synuclein misfolding inhibitor with potential disease-modifying effects. These emerging treatments aim to improve symptom management, reduce side effects, and slow disease progression, offering hope for significant advancements in Parkinson’s care.